EMAIL THIS PAGE TO A FRIEND

Infection and immunity

Damage to the blood-brain barrier during experimental cerebral malaria results from synergistic effects of CD8+ T cells with different specificities.


PMID 25156726

Abstract

CD8(+) T cells play a pathogenic role in the development of murine experimental cerebral malaria (ECM) induced by Plasmodium berghei ANKA (PbA) infection in C57BL/6 mice. Only a limited number of CD8(+) epitopes have been described. Here, we report the identification of a new epitope from the bergheilysin protein recognized by PbA-specific CD8(+) T cells. Induction and functionality of these specific CD8(+) T cells were investigated in parallel with previously reported epitopes, using new tools such as tetramers and reporter cell lines that were developed for this study. We demonstrate that CD8(+) T cells of diverse specificities induced during PbA infection share many characteristics. They express cytolytic markers (gamma interferon [IFN-γ], granzyme B) and chemokine receptors (CXCR3, CCR5) and damage the blood-brain barrier in vivo. Our earlier finding that brain microvessels in mice infected with PbA, but not with non-ECM-causing strains, cross-presented a shared epitope was generalizable to these additional epitopes. Suppressing the induction of specific CD8(+) T cells through tolerization with a high-dose peptide injection was unable to confer protection against ECM, suggesting that CD8(+) T cells of other specificities participate in this process. The tools that we developed can be used to further investigate the heterogeneity of CD8(+) T cell responses that are involved in ECM.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

38730 Citrate standard for IC, 1000 mg/L, analytical standard
C6H8O7
94676
Citric acid, certified reference material, TraceCERT®
C6H8O7
1134368
Citric acid, United States Pharmacopeia (USP) Reference Standard
C6H8O7
A1202000
Citric acid, anhydrous, European Pharmacopoeia (EP) Reference Standard
C6H8O7
PHR1071
Citric acid, Anhydrous, Pharmaceutical Secondary Standard; Certified Reference Material
C6H8O7
F7876
Folic acid, ≥97%
C19H19N7O6
F0300000
Folic acid, European Pharmacopoeia (EP) Reference Standard
C19H19N7O6
1286005
Folic acid, United States Pharmacopeia (USP) Reference Standard
C19H19N7O6
F8758
Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥97%
C19H19N7O6
F8798
Folic acid, meets USP testing specifications
C19H19N7O6
01769
Folic acid, tested according to Ph.Eur.
C19H19N7O6
PHR1035
Folic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C19H19N7O6
47866
Folic acid, analytical standard
C19H19N7O6
SRP3242 IL-2 from rat, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested
I0523 Interleukin-2 from mouse, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
I4161 Interleukin-2 from mouse, IL-2, recombinant, expressed in E. coli, carrier free
57600 Interleukin-2 human, ≥98.0% (GE), recombinant, expressed in E. coli, ~10000 U/mL
I2644 Interleukin-2 human, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
I7908 Interleukin-2 human, recombinant, expressed in Pichia pastoris, suitable for cell culture